For the interim period of FY2027, revenue was 469,961 million yen, up 17.5% year-over-year. Operating income was 41,429 million yen (up 20.4% YoY), and net income for the interim period was 31,270 million yen (up 20.9% YoY). The interim dividend remains 80 yen. Full-year forecasts are unchanged. By segment, the Pharmaceuticals business performed strongly; core operating income was 43.1 billion yen, reflecting foreign exchange effects and a change in the treatment of split profits.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4523","jir_company_name":"Eisai Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-10","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4523-20261110-01.pdf","jir_short_summary":"For the interim period of FY2027, revenue was 469,961 million yen, up 17.5% year-over-year. Operating income was 41,429 million yen (up 20.4% YoY), and net income for the interim period was 31,270 million yen (up 20.9% YoY). The interim dividend remains 80 yen. Full-year forecasts are unchanged. By segment, the Pharmaceuticals business performed strongly; core operating income was 43.1 billion yen, reflecting foreign exchange effects and a change in the treatment of split profits.","jir_summary":"### Performance Overview\nFor the second quarter of the fiscal year ending March 2027, consolidated results showed revenue of 469,961 million yen (YoY +17.5%), operating income of 41,429 million yen (+20.4%), and interim net income of 31,270 million yen (+20.9%). Growth was driven by strong sales of key products Lenvima, Leqembi, and Dayvigo, as well as foreign exchange effects. Core operating income was 43.1 billion yen, representing a robust increase of +28.6% year-over-year.\n\n### Shareholder Returns and Financial Position\nThe interim dividend is maintained at 80 yen, with a total annual dividend expected to be 160 yen including the year-end dividend. Assets and liabilities have increased, but cash and cash equivalents reached 317,466 million yen and free cash flow has improved. Sales expanded broadly across Japan, the U.S., China, EMEA, East Asia, and the Global South, with major pharmaceuticals such as Lenvima, Leqembi, and Dayvigo contributing to revenue.","jir_financial_highlights":"Revenue: 469,961 (Year-over-Year +17.5%)\nOperating Income: 41,429 (Year-over-Year +20.4%)\nInterim Net Income: 31,270 (Year-over-Year +20.9%)\nAnnual Dividend: 80 yen (Same as prior year)","jir_category":"","jir_hashtags":"#Eisai, #Earnings, #Interim, #PharmaceuticalsBusiness","jir_key_figures":"Revenue: 469,961 million yen (Year-over-Year +17.5%)\nOperating Income: 41,429 million yen (Year-over-Year +20.4%)\nInterim Net Income: 31,270 million yen (Year-over-Year +20.9%)","jir_meta_title":"Eisai Co., Ltd. Q2 FY2027 Interim Results | Revenue and Profits Exceed Prior Year","jir_meta_description":"Key points from Eisai Co., Ltd.'s Q2 FY2027 interim results: revenue 469,961 million yen, operating income 41,429 million yen, interim net income 31,270 million yen. Interim dividend maintained at 80 yen. Growth driven by the Pharmaceuticals segment.","jir_og_title":"Summary of Eisai Co., Ltd.'s Q2 FY2027 Interim Results","jir_og_description":"Eisai's interim results show year-over-year revenue growth and expanded profits. Interim dividend maintained at 80 yen; outlook unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7482,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-147176","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n